Vitura HealthASX:VIT Net Margin % is -1.23% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 957 Drug Manufacturers companies, Vitura Health ranks worse than 64.99% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Vitura Health's Net Income for the
six
months ended in Dec. 2025 was A$-0.8 Mil. Vitura Health's Revenue for the
six
months ended in Dec. 2025 was A$67.9 Mil. Therefore, Vitura Health's net margin for the quarter that ended in Dec. 2025 was -1.23%.
The historical rank and industry rank for Vitura Health's Net Margin % or its related term are showing as below:
ASX:VIT'
s Net Margin % Range Over the Past 10 Years
Min: -3175 Med: 2.76 Max: 11.77
Current: 0.61
ASX:VIT's Net Margin % is ranked worse than 64.99% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs ASX:VIT: 0.61
Vitura Health (ASX:VIT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vitura Health Net Margin % Related Terms
Vitura Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Vitura Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vitura Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a Net Margin % of -1.23% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vitura Health and its competitors. According to the industry distribution chart, Vitura Health ranks #622 out of 957 companies in the Drug Manufacturers industry, placing it in the top 65%.
Is Vitura Health's Net Margin % too high?
Vitura Health's current Net Margin % is -1.23%. Based on the distribution chart, Vitura Health ranks #622 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Vitura Health's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #622 out of 957 companies for Net Margin %. This places Vitura Health in the lower half of its industry. The industry median Net Margin % is 5.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Net Margin % is -1.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 73% below its estimated fair value. The current Net Margin % is -1.23%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Net Margin % is -1.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 